Mirum Pharmaceuticals, Inc. (MIRM)
Automate Your Wheel Strategy on MIRM
With Tiblio's Option Bot, you can configure your own wheel strategy including MIRM - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol MIRM
- Rev/Share 7.7574
- Book/Share 4.7711
- PB 9.3185
- Debt/Equity 1.3597
- CurrentRatio 3.2202
- ROIC -0.1378
- MktCap 2202312762.0
- FreeCF/Share -0.161
- PFCF -279.872
- PE -28.1046
- Debt/Assets 0.4595
- DivYield 0
- ROE -0.3363
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | MIRM | H.C. Wainwright | -- | Buy | -- | $73 | May 19, 2025 |
News
Mirum's Q1 Earnings Beat Estimates, 2025 Revenue View Raised
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Positive
MIRM reports better-than-expected first-quarter 2025 results. The company raises its 2025 revenue guidance.
Read More
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q1 Loss, Tops Revenue Estimates
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Negative
Mirum Pharmaceuticals, Inc. (MIRM) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to loss of $0.54 per share a year ago.
Read More
Mirum Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025
Published: April 30, 2025 by: Business Wire
Sentiment: Neutral
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025.
Read More
Mirum's Heavy Dependence on Livmarli for Revenues Remains a Woe
Published: March 21, 2025 by: Zacks Investment Research
Sentiment: Negative
MIRM's high reliance on lead drug, Livmarli for revenues remains a worry. Failure to generate sufficient revenues from Livmarli sales is likely to hurt the stock.
Read More
Wall Street Analysts Predict a 26.18% Upside in Mirum Pharmaceuticals (MIRM): Here's What You Should Know
Published: February 26, 2025 by: Zacks Investment Research
Sentiment: Positive
The mean of analysts' price targets for Mirum Pharmaceuticals (MIRM) points to a 26.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read More
Mirum Pharmaceuticals (MIRM) is on the Move, Here's Why the Trend Could be Sustainable
Published: February 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Mirum Pharmaceuticals (MIRM) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Read More
About Mirum Pharmaceuticals, Inc. (MIRM)
- IPO Date 2019-07-18
- Website https://www.mirumpharma.com
- Industry Biotechnology
- CEO Mr. Christopher Peetz
- Employees 334